Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02614534 |
|
Recruitment Status :
Recruiting
First Posted : November 25, 2015
Last Update Posted : September 7, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colorectal Cancer | Drug: MITOMYCIN-C 40 mg | Phase 3 |
The purpose of this study is to determine whether Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma is effective in the treatment of locally advanced colorectal carcinoma.
The Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) is expected to be an effective treatment with minimal side effects, it has already provided clear benefits in terms of overall survival in patients with advanced cancer.
This is an attractive option for the healthcare professionals who face daily to peritoneal recurrence after performing complex surgeries, however its application is difficult due to the cost and resources increase. This leads to the necessity of administering the treatment within a clinical trials and in order to obtain a significant power this clinical trials will be multicenter and it will be performed in several Oncological surgery Units highly specialised and with extensive experience in colorectal carcinoma.
| Study Type : | Interventional (Clinical Trial) |
| Official Title: | Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma |
| Study Start Date : | November 2015 |
| Estimated Primary Completion Date : | October 2020 |
- Locoregional Control (LC) [ Time Frame: 3 years ]Time elapsed from the surgical intervention clinical up to the date the patient is free of clinical and radiological locoregional recurrence
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
Inclusion Criteria:
- Male and female patients between the ages of 18 and 75 years;
- Adenocarcinoma of the colon, sigma and colon-sigma joint which represent cT4a/b in line with The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual;
- Lymph node involvement: N0, the presence of N1/2 according to the 7th edition of the AJCC is allowed, provided that they can be resectable;
- Metastatic extent: M0;
- Karnofsky index >70 or Performance status ≤2;
- Informed consent properly completed.
Exclusion Criteria:
- Presence of metastasis (M1);
- Presence of unresectability criteria;
- Urgent intervention for obstruction or perforation;
- Extraperitoneal rectal cancer (avoiding alterations for neoadyuvance);
- Coexistence with another malignant neoplastic disease;
- Severely altered liver, kidney and cardiovascular function;
- Intolerance to treatment;
- Administration of chemotherapy before the trial (use of neoadyuvance is discarded);
- Pregnant or breastfeeding women.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02614534
| Contact: Blanca Quijano Ruiz, Pharmacist | (+34) 957 736 484 | blanca.quijano@imibic.org |
| Spain | |
| Hospital Universitario Reina Sofía | Recruiting |
| Córdoba, Spain, 14004 | |
| Contact: Blanca Quijano Ruiz, Pharmacist (+34) 957 736 484 blanca.quijano@imibic.org | |
| Principal Investigator: Alvaro Arjona, MD | |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Maimónides Biomedical Research Institute of Córdoba |
| ClinicalTrials.gov Identifier: | NCT02614534 History of Changes |
| Other Study ID Numbers: |
FCO-HIP-2015-01 |
| First Posted: | November 25, 2015 Key Record Dates |
| Last Update Posted: | September 7, 2016 |
| Last Verified: | September 2016 |
Additional relevant MeSH terms:
|
Colorectal Neoplasms Fever Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |
Rectal Diseases Body Temperature Changes Signs and Symptoms Mitomycins Mitomycin Antibiotics, Antineoplastic Antineoplastic Agents Alkylating Agents Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors |